Eugene

[email protected]

LATEST

Endo CEO To Step Down; Company Implements Succession Plan
By

By
Endo International, a generics and specialty branded pharmaceuticals company, has announced that Paul V. Campanelli, President and Chief Executive Officer (CEO) has notified the company’s Board of Directors of his…

Takeda To Divest Select Products to Stada in $660-Million Deal
By

By
Takeda Pharmaceutical has agreed to divest a portfolio of 20 select products to Stada Arzneimittel, a generics and specialty pharmaceuticals company, for a total value of $660 million. The portfolio…

Sandoz Receives FDA Approval for Biosimilar of Amgen’s Neulasta
By

By
Sandoz, a Novartis Company, has received US Food and Drug Administration (FDA) approval for its biosimilar, Ziextenzo (pegfilgrastim-bmez), the biosimilar to Amgen’s Neulasta (pegfilgrastim), for treating febrile neutropenia. Neulasta is…

Novartis Has Setback for Gene Therapy Zolgensma
By

By
The US Food and Drug Administration (FDA) has placed a partial hold on clinical trials for the intrathecal administration of Novartis’ Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy, or AVXS-101. AveXis,…

Global Pharma Briefs: News from Europe and Asia
By

By
A roundup of developments and latest news from Germany (AstraZeneca, Takeda) and India (Zydus Cadila). Europe AstraZeneca to Divest Rights to Cheplapharm for Seroquel Products in EU and Russia AstraZeneca…

President Trump Plans to Nominate New FDA Commissioner
By

By
President Donald J. Trump has announced his intent to nominate Dr. Stephen Hahn, Chief Medical Executive at the University of Texas MD Anderson Cancer Center (MDACC), to be the next…

Roche, Dicerna Form $1.67-Bn Deal for Hepatitis B Treatments
By

By
Roche has formed a research collaboration and licensing agreement with Dicerna Pharmaceuticals, a developer of RNAi medicines, in a deal worth up to $1.67 billion focused on developing treatments for…

Bayer Completes $585-Million Sale of Dr. Scholl’s to Investment Firm
By

By
Bayer has completed the sale of its Dr. Scholl’s consumer footcare business to Yellow Wood Partners, a Boston-based private investment firm, for a purchase price of $585 million. Dr. Scholl’s…

Amgen, BeiGene in $2.7-Bn Oncology Pact for China
By

By
Amgen has entered into a global strategic oncology collaboration with BeiGene, a Beijing-headquartered company, under which Amgen will acquire an equity stake in BeiGene for approximately $2.7 billion. The companies…

Arranta Bio Launches as New CDMO; Partners with Thermo Fisher
By

By
Arranta Bio, a new CDMO that focuses on the human microbiome, has completed an $82 million funding round and formed a strategic partnership with Thermo Fisher Scientific. Arranta was formed…